Alpa Laboratories Reports Significant PAT Growth Amid Declining Net Sales in August 2025

Alpa Laboratories, a microcap player in the Pharmaceuticals & Biotechnology sector, has recently reported its financial results for the quarter ending June 2025. The results, declared on August 13, 2025, indicate a notable adjustment in evaluation, with the score shifting to 4 from -4 over the past three months.
The financial data reveals a significant growth in Profit After Tax (PAT), which reached Rs 11.77 crore, marking a 140.6% increase compared to the average PAT of the previous four quarters. This figure represents the highest PAT recorded in the last five quarters, suggesting a positive near-term trend in profitability. Additionally, Earnings per Share (EPS) also peaked at Rs 5.59, reflecting enhanced earnings for shareholders.

Conversely, the company faced challenges with its net sales, which fell to Rs 19.11 crore, a decline of 32.0% from the average of the previous four quarters and the lowest figure in the last five quarters. Furthermore, the reliance on non-operating income, which constituted 101.44% of Profit Before Tax, raises concerns about the sustainability of the business model.

For more insights on Alpa Laboratories and its financial performance, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.